Gyon Technologies Capital Management, LP Abb Vie Inc. Transaction History

Gyon Technologies Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $398,134 - $506,159	-2,893 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $4.69 Million - $5.82 Million	-35,559 Reduced 92.48%	2,893 $469,000
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $2.31 Million - $2.92 Million	21,501 Added 126.84%	38,452 $5.21 Million
Q3 2021 Nov 18, 2021	BUY	$106.4 - $120.78 $1.8 Million - $2.05 Million	16,951 New	16,951 $1.83 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $306,792 - $341,784	-2,916 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $83,067 - $91,447	-812 Reduced 21.78%	2,916 $316,000
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $136,913 - $184,847	-1,701 Reduced 31.33%	3,728 $399,000
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $466,405 - $547,406	5,429 New	5,429 $476,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $460,616 - $616,374	-6,278 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $404,931 - $613,925	6,278 New	6,278 $478,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.